WO2007118431A1 - Trap 蛋白自身作为活性成分在制备治疗金黄色葡萄球菌感染的药物中的应用 - Google Patents
Trap 蛋白自身作为活性成分在制备治疗金黄色葡萄球菌感染的药物中的应用 Download PDFInfo
- Publication number
- WO2007118431A1 WO2007118431A1 PCT/CN2007/001246 CN2007001246W WO2007118431A1 WO 2007118431 A1 WO2007118431 A1 WO 2007118431A1 CN 2007001246 W CN2007001246 W CN 2007001246W WO 2007118431 A1 WO2007118431 A1 WO 2007118431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trap protein
- trap
- protein
- aureus
- staphylococcus aureus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- TRAP protein itself as active ingredient in preparing medicine for treating Staphylococcus aureus infection
- the present invention belongs to the field of biopharmaceuticals, and in particular relates to the use of TRAP protein itself as an active ingredient in the preparation of a medicament for treating S. aureus infection. Background technique
- Staphylococcus aureus (Y «s 7 F7oi?. si/rei/s) is a genus of Staphylococcus, an important pathogen of humans, capable of causing pneumonia, endocarditis, burns and wound infections, sepsis, toxic Shock and other serious infections. Staphylococcus aureus is also a bacterium that causes food poisoning. Staphylococcus aureus is widely distributed in air, soil, water and utensils. Humans and animals have a high rate of infection. Staphylococcus aureus is capable of large-scale spread through contact with sputum in densely populated areas. Each year, the number of people infected with Staphylococcus aureus in hospitals alone exceeds several million. It is the main pathogen of gram-negative bacterial sepsis and an important pathogen for burn wound infection and acute liver failure.
- RNAI II The main pathogenic substances of Staphylococcus aureus are exotoxins, including hemolytic toxins, leukocidin, enterotoxin and the like. Recent studies have shown that the synthesis of these virulence factors of S. aureus is controlled by a modulating MA molecule, RNAI II.
- RNAII I activates gene transcription of virulence factors and regulates translation of virulence factors by base complementation. In the early logarithm of bacterial growth, its RNAI II level is low, but the logarithmic RNAI II level is increased by 40-fold, while the level of RNAII I is a MAI II activator secreted by S. aureus itself (RM II I act ivat).
- the ing protein hereinafter referred to as RAP
- RAP The ing protein, hereinafter referred to as RAP
- RAP is also known as the Staphylococcus aureus virulence stimulating factor.
- Staphylococcus aureus continues to secrete RAP, which activates virulence factors only after RAP reaches a certain concentration.
- Staphylococcus aureus without RAP itself does not Pathogenicity (Balaban, . et al. Science 1995, 280, 438-440).
- TRAP 21kD RNAIII activating protein
- the TRAP protein consists of 167 amino acids and has His kinase activity. TRAP protein begins to phosphorylate early in the growth of S. aureus and reaches its maximum level in the mid-log phase. After RAP action, signal transduction through autophosphorylation mediates intracellular RNAIII levels and accelerates the secretion of S. aureus exotoxin (Naomi B, et al, J. Biol. Chem 2001, 276: 2658- 2667) 0 TRAP protein is a S. aureus surface protein that is highly conserved in Staphylococcus. The main biological function of TRAP protein is involved in the regulation of S. aureus toxin.
- TRAP proteins As the phosphorylation level of TRAP protein increases, the exotoxin level of S. aureus is up-regulated (Gov Y, et al. / Biol Chem 2004, 279: 14665). -72) According to the sequence alignment analysis, the TRAP proteins that have been found so far can be divided into three families, and the homology between them is greater than 80% (Yang G, et al. 2005 J. Biol. Chem. 280:27431 -27435 ). Specifically, TRAP proteins were highly conserved among S. aureus and S. epidermidis by sequence alignment. There are currently 10 TRAP protein sequences of S. aureus and 2 S. epidermidis registered at Gene Bank.
- Family 1 includes 7 kinds of TRAP proteins derived from Staphylococcus aureus.
- the agreement is analyzed by DNAMAN software, the agreement is 99.49% (Fig. 1);
- Family 2 includes 3 kinds of Staphylococcus aureus.
- the source of TRAP protein was analyzed by DNAMAN software with a consistency of 99.80% (Fig. 2);
- Family 3 included two species of TRAP proteins derived from Staphylococcus epidermidis, which were analyzed by DNAMAN software with a consistency of 98.20% (Fig. 3).
- aureus 04018 and Staphylococcus epidermidis ATCC12228 were selected from three families. Sequence alignment analysis was performed using DNAMAN software with a consistency of 84.72% (Fig. 4). The study found that by using exogenous RAP and TRAP inhibitors to inhibit the RAP and TRAP pathways produced by S. aureus toxin, the pathogenic effect of S. aureus can be effectively reduced.
- Known inhibitors of RAP and TRAP such as RNAI II inhibiting pept ide (RIP) and antibodies, can effectively reduce the secretion of S. aureus exotoxin.
- the C-terminus of the TRAP protein can be an effective peptide vaccine to protect the body against infections caused by S.
- the main method to solve the problem of Staphylococcus aureus infection is to inhibit the passage of the above-mentioned Staphylococcus aureus toxin to reduce the production of Staphylococcus aureus toxin, such as by RIP, RAP antibody, etc., thereby reducing the pathogenicity of Staphylococcus aureus. effect.
- a DNA sequence and amino acid sequence of a target protein (TRAP) of RNAI I I activator from S. aureus RN6390B is known (see U.S. Patent No. 6,689,878). Furthermore, the use of the TRAP protein for inducing antibody production and using the obtained antibody as a drug has been reported (see, US Pat. No. 6, 747, 129), which discloses the inhibition of TRAP by a monoclonal antibody or a polyclonal antibody of TRAP. Protein, thereby inhibiting the production of S. aureus infection.
- Staphylococcus aureus due to the abuse of antibiotics, the resistance of pathogenic bacteria including Staphylococcus aureus is continuously produced and enhanced.
- the resistant strains include methicillin resistant to ⁇ -lactam antibiotics.
- Staphylococcus aureus (MRSA), glycopeptide antibiotic-resistant peptides of Staphylococcus aureus (GISA), vancomycin-resistant Staphylococcus aureus (VRSA), etc. make many commonly used antibiotics ineffective.
- Staphylococcus aureus itself is highly susceptible to drug resistance.
- One aspect of the invention relates to the use of the TRAP protein itself as an active ingredient in the manufacture of a medicament for the treatment of S. aureus infection.
- the exogenous TRAP protein itself is in a cell model as well as in an animal model outside of Staphylococcus aureus.
- the production of toxins has a good inhibitory effect.
- the exogenous TRAP protein itself can be used as an active ingredient to treat Staphylococcus aureus infection and reduce the pathogenicity of Staphylococcus aureus, and the therapeutic effect is similar to that of the TRAP protein polyclonal antibody.
- the "exogenous TRAP protein” refers to a process of producing a staphylococcal exotoxin in S. aureus after infection with a cell model or an S. aureus-infected animal model.
- the artificially added or administered TRAP protein is referred to as an exogenous TRAP protein.
- the MDB1 [cell model is used with or without the addition of exogenous TRAP protein while adding S. aureus to the MDBK cell culture.
- the results showed that the addition of exogenous TRAP protein can effectively inhibit the production of S. aureus exotoxin.
- S. aureus was injected intraperitoneally into the mice, and then the exogenous TRAP protein was injected intraperitoneally or not. The survival time and survival status of the mice in each group were observed. The results showed that the injection of exogenous TRAP protein can effectively reduce S. aureus infection in mice increases the survival rate of infected mice.
- the TRAP protein includes a natural TRAP protein derived from different S. aureus species, a TRAP protein obtained by, for example, chemical synthesis, by a recombinant TRAP protein or a fusion TRAP protein prepared by, for example, a genetic engineering method. Or a chemically modified TRAP protein derivative.
- the TRAP proteins of the present invention also include biologically active fragments derived from intact TRAP proteins that retain all or part of the biological activity, some of which may also have higher biological activity than TRAP proteins. Fragments of the TRAP protein are also used to treat S. aureus infections.
- a TRAP protein as used in the present invention refers to a protein having sequence identity to the sequence set forth in SEQ ID NO. 2 or 4, or an ortholog thereof, including at least 70%, at least 80%, at least 90%, At least 95% at least 98%, or a protein with 100% sequence identity.
- the present invention also encompasses a TRAP protein having at least 70%, at least 80%, at least 90 of amino acid sequence residues 1 to 167, residues 30 to 167, or residues 50 to 167 of SEQ ID NO. 2 or 4. %, at least 95% or more than 95% sequence identity.
- the TRAP protein sequence is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and shown in Figure 1-3, respectively, belonging to three different protein families. 12 different sources of TRAP protein.
- the percent identity between two amino acid sequences can be determined, for example, by the Needelman-Wunsch alignment, and can be used for protein and DNA alignments.
- the default scoring matrix used is BLOSUM50, a residue in the interval The penalty is -12, and the penalty for additional residues in the interval is -2.
- the alignment can be done by the FASTA package, version v20u6 (WR Pearson and DJ Lipman (1988), "Improved Tools for Biological Sequence Analysis", PMS 85: 2444-2448; and WR Pearson (1990) "Comparison of Fast and Sensitive Sequences Using FASTP and FASTA", Enzymology Method 183: 63-98).
- the TRAP protein of the present invention may be any known TRAP protein. From its structure and source, the TRAP protein may be the same or different from the endogenous TRAP protein produced by the S. aureus itself in the S. aureus infection to be treated. The present inventors have found that a variety of different TRAP proteins derived from S. aureus strains have the same or similar effects of inhibiting the production of S. aureus exotoxin and reducing the pathogenicity of S. aureus.
- a TRAP protein (nucleotide sequence corresponding to GenBankTM acceptance number: AF202641) obtained from S. aureus RN6390B is used as an active ingredient, and is used as an active ingredient. Effective inhibition of S. aureus exotoxin production in in vitro and in vivo experiments.
- a TRAP protein (corresponding to a nucleotide sequence of GenBankTM Acceptance No.: AY248703) as shown in SEQ ID NO: 4 obtained from S. aureus 04018 is used as an active ingredient, It is used to inhibit the production of S.
- aureus exotoxin in vitro and in vivo, and to treat Staphylococcus aureus infection.
- a fusion protein of a TRAP protein and a 12 amino acid polypeptide is used for inhibiting S. aureus exotoxin production in vitro and in vivo to treat S. aureus infection.
- a further aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the TRAP protein as an active ingredient and optionally a pharmaceutically acceptable carrier or excipient.
- a TRAP protein or an active fragment thereof for treating S. aureus infection may be administered alone or in combination with a pharmaceutically acceptable carrier or excipient, in a single dose or in multiple doses.
- composition of the present invention may be combined with a pharmaceutically acceptable carrier or diluent, and any other known adjuvants or excipients, as disclosed in Remington: Science and Practice of Pharmacology , 19th edition, Gennaro, Ed., Mack Publ i shing Co., Eas ton, PA, 1995.
- the compositions may be presented in conventional forms such as solutions, suspensions, lyophilized powders, capsules, tablets or aerosols and the like.
- compositions may be specially formulated for administration by any suitable route, such as parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal), oral, rectal, nasal, pulmonary, Local (including frequency and sublingual), transdermal, intracranial, intraperitoneal, vaginal route.
- parenteral including subcutaneous, intramuscular, intrathecal, intravenous and intradermal
- oral rectal
- nasal pulmonary
- Local including frequency and sublingual
- transdermal intracranial, intraperitoneal, vaginal route.
- the route of administration may be any route as long as it allows the active ingredient to be efficiently transported to a suitable or desired site of action.
- compositions for parenteral administration including sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions, and sterile powders or lyophilized powders, before use, in sterile injectable solutions Or reconstitution in the dispersion. It is also within the scope of the inventive concept to store the preparation for injection.
- compositions for oral administration include solid dosage forms such as hard or soft gums, tablets, lozenges, dragees, pills, troches, powders and granules. Where appropriate, they may be formulated with a coating, such as an enteric coating, or formulated according to methods well known in the art to allow for controlled release of the active ingredient, such as sustained or extended release.
- Liquid dosage forms for oral administration include solutions, emulsions, aqueous or oily suspensions, syrups and elixirs.
- Suitable modes of administration include: suppositories, sprays, cartilage, breast bones, gels, inhalants, dermal patches, implants, and the like.
- One dose or multiple doses, such as 1 to 3 doses, are administered to about 10 mg/kg body weight.
- the exact dose will depend on the condition of the S. aureus infection being treated, the frequency and manner of administration, the sex, age, weight and general condition of the subject being treated, the type and severity of the condition being treated, any Concomitant diseases and other factors known to those skilled in the art.
- the formulation can conveniently be presented in unit dosage form by methods well known in the art.
- the dosage form for parenteral administration such as intravenous, intrathecal, intramuscular, and the like, is administered one or more times a day (eg, one to three times per day).
- the typical dosage form may comprise from 0.001 to about 1 01mg ⁇ 100mg ⁇ For example, from about 0. lmg to about 100mg.
- 5 mg from ⁇ 0 mg to about 500 mg, for example from about 0. 5 mg, from about 0. 5 mg to about 500 mg, and from about 0. 5 mg. Up to about 200mg.
- Suitable pharmaceutical carriers include inert solid dilute dances or fillers, sterile aqueous solutions, and various organic solvents.
- solid carriers are lactose, succulent, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
- liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
- the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or in admixture with a wax.
- compositions formed by combining TRAP proteins or active fragments thereof with a pharmaceutically acceptable carrier for treating S. aureus infections according to the present invention may be conveniently administered in a variety of dosage forms suitable for the disclosed routes of administration.
- the formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
- the aqueous suspension may comprise a TRAP protein or an active fragment thereof, which is admixed with excipients suitable for the production of aqueous suspensions.
- the excipient is a suspending agent, such as sodium carboxycarboxylate, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, Astragalus gum and gum arabic;
- the dispersing or wetting agent may be a naturally occurring phospholipid, such as lecithin, or a condensation product of an alkylene oxide with a fatty acid, such as polyoxyethylene stearate, or ethylene oxide with a long chain aliphatic a condensation product of an alcohol, such as heptadecylethyleneoxyhexadecanol, or a condensation product of ethylene oxide with a portion of a fatty acid-derived ester and a hexitol, such as polyoxyethylene sorbitan monooleate, or ethylene oxide with A condensation
- An oily suspension can be formulated by dispersing the active ingredient in a vegetable oil (such as peanut oil, olive oil, sesame oil or coconut oil) or dispersion in a mineral oil such as liquid paraffin.
- the oily suspensions may include a viscous agent such as beeswax, hard paraffin or cetyl alcohol. Sweeteners and flavoring agents as listed above may be added to prepare a palatable oral preparation. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders or granules suitable for preparing aqueous suspensions by the addition of water admix the active compound with dispersion or wetting agents, suspending agents and one or more preservatives can be exemplified by those already mentioned above.
- Other excipients such as sweeteners, flavoring agents, and coloring agents can also be used.
- the pharmaceutical composition for treating a TRAP protein infected with S. aureus or an active fragment thereof may also be in the form of an oil-in-water emulsion.
- the oil phase can be a vegetable oil (such as olive oil or peanut oil), or a mineral oil (such as liquid paraffin), or a mixture thereof.
- Suitable emulsifiers may be naturally occurring gums such as gum arabic or tragacanth; naturally occurring phospholipids such as soy, lecithin, fatty acid and hexitol anhydride derived esters or partial esters such as sorbitan mono-oil The acid ester, and the condensation product of the partial ester with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweeteners and flavoring agents.
- compositions may also be administered in the form of a suppository for rectal administration of a compound of the invention.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient. Preparation, the excipient is solid at ordinary temperatures, but liquefies at rectal temperature and thus melts in the rectum to release the drug.
- suitable non-irritating excipient Preparation, the excipient is solid at ordinary temperatures, but liquefies at rectal temperature and thus melts in the rectum to release the drug.
- shields include, for example, cocoa butter and polyethylene glycol.
- creams, soft cyan, jelly, suspension solutions and the like containing the compound of the present invention are contemplated.
- topical application should include oral rinses and gargles.
- the TRAP protein or active fragment thereof for use in the treatment of S. aureus infection according to the present invention may also be administered in the form of a liposome delivery system, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- the lipid body can be composed of different phospholipids, such as cholesterol, stearamide or phosphatidylcholine.
- a part of the TRAP protein or an active fragment thereof for treating S. aureus infection may form a solvate with water or a common organic solvent.
- Such solvates are also included within the scope of the invention.
- the preparation may be in the form of a tablet, in the form of a powder or pellet, or in the form of a tablet or lozenge.
- the amount of solid carrier will vary widely, but will generally range from about 25 mg to about lg.
- the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or nonaqueous liquid suspension or solution.
- the TRAP protein or active fragment thereof for use in the treatment of S. aureus infection according to the present invention can be administered to a mammal, particularly a human, in need of such treatment. Mammals also include animals, whether they are tamed animals (such as domestic pets) or non-tamed animals (such as wild animals).
- a pharmaceutical composition comprising a compound according to the invention may be administered one or more times daily or weekly.
- An effective amount of the pharmaceutical composition is an amount that achieves a clinically significant effect.
- the dosage will depend, in part, on the particular condition being treated, the age, weight and general health of the subject, as well as other factors that are apparent to those skilled in the art.
- Another aspect of the invention relates to a method for treating a Staphylococcus aureus infection
- the method comprises administering to a subject suffering from S. aureus infection a therapeutically effective amount of a pharmaceutical composition comprising the TRAP protein itself as an active ingredient.
- treatment refers to the state in which a patient is treated and cared for against Staphylococcus aureus infection.
- the term is intended to include the full range of treatments for S. aureus infection, including alleviation and alleviation of symptoms and complications, and/or cure or elimination of diseases, disorders and symptoms.
- the subject to be treated is preferably a mammal, especially a human.
- the term "therapeutically effective amount” means an amount sufficient to treat the disease state. It can vary depending on the patient, the condition to be treated, and the method of treatment employed. For bacterial infections, particularly S. aureus infections, the therapeutically effective amount refers to the amount required to successfully control or eliminate the infection after infection has occurred.
- the TRAP protein or a biologically active fragment thereof for treating S. aureus infection can be administered alone or in combination with other established therapeutic methods.
- TRAP proteins have a dual role in the protection against S. aureus infection, that is, the protein itself and its inhibitor or neutralizing antibody will achieve the same effect, and it will represent a new class of drug action modes.
- TRAP for the treatment of S. aureus infections necessarily results in the production of antibodies against TRAP in human organisms (because TRAP is a bacterial-derived foreign protein).
- the production of antibodies means inhibition of the action of the drug, but for TRAP, the antibodies produced are just as useful.
- the advantages of the invention are:
- the present invention explores a new use of TRAP protein in the preparation of a drug, and opens up a new field of using bacterial cell membrane-associated proteins for the preparation of therapeutic drugs, which represents a completely new drug mode.
- the TRAP protein of the present invention does not find homologous sequences in the human genome, and thus does not cause human immunological diseases.
- the TRAP protein inhibits the production of toxins by S. aureus, and also stimulates the body to produce corresponding antibodies, and the produced antibodies can further exert the effect of inhibiting the production of exotoxin of S. aureus. At the same time, the antibody produced by this protein continues to exert the same mode of action to provide a new mode of drug action.
- FIG. 1 Comparison of TRAP protein sequence alignments from seven different sources in TRAP protein family 1.
- Figure 4 Comparison of the three TRAP protein families from the TRAP protein sequence alignment of three different strains.
- Figure 5 Bar graph of the effect of exogenous TRAP proteins from different sources on the production of S. aureus exotoxin. Among them, the numbers represent the source of TRAP: l. GenBank TM acceptance number: AF202641 protein group; 2. GenBank TM acceptance number: AY248703; 3. Natural TRAP protein group purified from S. aureus; 4. TRAP protein and I A fusion protein composed of a polypeptide of 2 amino acids; 5. a normal cell control; 6. a saline control group. Figure 6. Bar graph of the effect of exogenous TRAP protein on TRAP antibody production in mice. Among them, 1. TRAP treatment group 2. Saline control group 3. Negative control. detailed description
- TRAP protein (GenBankTM acceptance number: AF202641/AY248703)
- primers were designed according to the base sequence of GenBank, and the TRAP gene was amplified from the genomes of RN6390B and 04018 by PCR, and cloned into pET-28a.
- the vector was transformed into Escherichia coli, induced by IPTG, and purified by Ni 2+ affinity resin to obtain two corresponding TRAP proteins.
- TRAP protein Preparation of natural TRAP protein
- the recombinant TRAP protein was used to prepare the polyclonal antibody.
- the recombinant TRAP protein was coupled with CNBr-activated Sepherose 4B to prepare the affinity antibody to purify the antibody, and the purified antibody was coupled with CNBr-activated Sepherose 4B by affinity purification.
- the TRAP protein was purified from the S. aureus RN6390B ultrasonic supernatant and further purified by HPLC to obtain a naturally purified TRAP protein with a purity greater than 95%.
- a fusion protein consisting of a TRAP protein and a 12 amino acid polypeptide: selection of an unrelated peptide sequence (TPSIPSLWTTP-Sinking et al, Cellular and Molecular Immunol. 2002, 18: 623-626), designing primers, obtaining TRAP by PCR - Gene sequence of an unrelated peptide fusion protein, cloned into ET-28a vector, by IPTG The expression was induced, transformed into Bacillus cerevisiae, and purified by Ni 2+ affinity resin to obtain a fusion protein composed of a TRAP protein and a 12 amino acid polypeptide.
- TPSIPSLWTTP-Sinking et al Cellular and Molecular Immunol. 2002, 18: 623-626
- primers designing primers, obtaining TRAP by PCR - Gene sequence of an unrelated peptide fusion protein, cloned into ET-28a vector, by IPTG
- the expression was induced, transformed into Bacillus
- the MTT method was used to detect the effects of various sources of TRAP protein on S. aureus exotoxin in the MDBK cell model (Normano G. et al 2001 Microbiologica 24, 341-346). The specific steps are as follows:
- centrifuge (10, 000 rpm / 5 min), collect the supernatant, boil for 10 minutes, and centrifuge again (10, 000 rpm / 5 min) to collect the supernatant;
- Inoculate MDBK cells in a 96-well plate (DMEM 10% fetal bovine serum), 1x104/well, and incubate for 4 hours in a C02 incubator at 37 °C;
- the supernatant obtained in step 4) is added to the MDBK cell culture solution ( ⁇ /well), and cultured in a C02 incubator for 37 hours;
- mice were purchased from the Animal Center of the Academy of Military Medical Sciences, and the remaining materials were the same as in Preparation Example 1 and Preparation Example 3.
- TRAP protein can effectively reduce the infection of S. aureus in mice and increase the survival rate of infected mice (see Table 1).
- Group 1 is TRAP ( GenBankTM Acceptance No.: AF202641) protein treatment group; Group 1 is TRAP ( GenBank TM acceptance number: AY248703 ) protein treatment group; Group 3 is fusion protein treatment of TRAP protein and 12 amino acid polypeptide Group; Group 4 was a saline control group.
- TRAP GenBankTM Acceptance No.: AF202641
- TRAP GenBank TM acceptance number: AY248703
- Group 3 is fusion protein treatment of TRAP protein and 12 amino acid polypeptide Group
- Group 4 was a saline control group.
- TRAP GenBankTM Acceptance No.: AF202641
- Mouse serum was collected one month later, and the production of TRAP antibody in mice was determined by ELISA;
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/226,491 US20090305975A1 (en) | 2006-04-17 | 2007-04-16 | Use of Trap Protein Per se as an Active Ingredient for the Manufacture of a Medicament for the Treatment of Staphylococcus Aureus Infection |
KR1020087027806A KR101443233B1 (ko) | 2006-04-17 | 2007-04-16 | 황색포도상구균 감염 치료용 의약을 제조하기 위한 활성 성분으로서의 trap 자체의 용도 |
JP2009505708A JP2009533478A (ja) | 2006-04-17 | 2007-04-16 | 黄色ブドウ球菌感染症の治療用薬剤の製造のための活性成分としてtrapタンパク質自体の使用 |
EP07720819A EP2011508B1 (en) | 2006-04-17 | 2007-04-16 | Use of trap protein per se as active ingredient for manufacturing a medicament for the treatment of staphylococcus aureus infection |
CA002649768A CA2649768A1 (en) | 2006-04-17 | 2007-04-16 | Use of trap protein per se as an active ingredient for the manufacture of a medicament for the treatment of staphylococcus aureus infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100756387A CN100540047C (zh) | 2006-04-17 | 2006-04-17 | Trap蛋白在制备治疗金黄色葡萄球菌感染的药品中的应用 |
CN200610075638.7 | 2006-04-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007118431A1 true WO2007118431A1 (zh) | 2007-10-25 |
WO2007118431A8 WO2007118431A8 (zh) | 2009-07-30 |
Family
ID=37483043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/001246 WO2007118431A1 (zh) | 2006-04-17 | 2007-04-16 | Trap 蛋白自身作为活性成分在制备治疗金黄色葡萄球菌感染的药物中的应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090305975A1 (zh) |
EP (1) | EP2011508B1 (zh) |
JP (1) | JP2009533478A (zh) |
KR (1) | KR101443233B1 (zh) |
CN (1) | CN100540047C (zh) |
CA (1) | CA2649768A1 (zh) |
WO (1) | WO2007118431A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101855594B1 (ko) | 2016-10-17 | 2018-06-08 | 국방과학연구소 | 황색포도상구균 장독소 b형의 돌연변이로 독성활성이 제거된 황색포도상구균 장독소 b형 백신 및 이의 제조방법 |
CN115927674A (zh) * | 2022-08-12 | 2023-04-07 | 中国科学院大学宁波华美医院 | 一种检测金黄色葡萄球菌的cda引物组、试剂盒及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689878B2 (en) | 1998-09-15 | 2004-02-10 | The Regents Of The University Of California | Target of RNAIII activating protein (TRAP) |
WO2005009396A2 (en) * | 2003-02-03 | 2005-02-03 | Naomi Balaban | Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5694546A (en) * | 1994-05-31 | 1997-12-02 | Reisman; Richard R. | System for automatic unattended electronic information transport between a server and a client by a vendor provided transport software with a manifest list |
JPH10326289A (ja) * | 1997-03-28 | 1998-12-08 | Nippon Telegr & Teleph Corp <Ntt> | 情報提供方法、システムおよびそのプログラムを格納した記憶媒体 |
US7219123B1 (en) * | 1999-10-08 | 2007-05-15 | At Road, Inc. | Portable browser device with adaptive personalization capability |
US7630986B1 (en) * | 1999-10-27 | 2009-12-08 | Pinpoint, Incorporated | Secure data interchange |
KR100357261B1 (ko) * | 1999-12-30 | 2002-10-18 | 엘지전자 주식회사 | 멀티미디어 데이터의 의미적/구조적 정보 생성방법 및 그 정보의 기록매체와 멀티미디어 검색 및 브라우징 방법 |
EP1168223A1 (en) * | 2000-06-27 | 2002-01-02 | YYY Net Co. Ltd. | Internet advertisement system |
JP3527211B2 (ja) * | 2000-08-01 | 2004-05-17 | 日立マクセル株式会社 | 電子クーポン・システム |
US20020083145A1 (en) * | 2000-12-22 | 2002-06-27 | Nortel Networks Limited | Method and system for online/offline services |
GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
US7099871B2 (en) * | 2001-05-04 | 2006-08-29 | Sun Microsystems, Inc. | System and method for distributed real-time search |
US20030130887A1 (en) * | 2001-10-03 | 2003-07-10 | Thurston Nathaniel | Non-deterministic method and system for the optimization of a targeted content delivery |
US6996579B2 (en) * | 2001-11-02 | 2006-02-07 | At&T Corp. | E-coupon service for location-aware mobile commerce which determines whether to supply requested e-coupons based on the number of requests received in a processing cycle, and a threshold number of requests required to make expected returns from redeemed coupons greater than advertising fees |
US7286651B1 (en) * | 2002-02-12 | 2007-10-23 | Sprint Spectrum L.P. | Method and system for multi-modal interaction |
US8095589B2 (en) * | 2002-03-07 | 2012-01-10 | Compete, Inc. | Clickstream analysis methods and systems |
CA2639010C (en) * | 2002-09-26 | 2010-12-21 | Video Furnace, Inc. | Digital content delivery and viewing system and method |
US20060235938A1 (en) * | 2002-11-12 | 2006-10-19 | Pennell Mark E | System and method for delivery of information based on web page content |
US7155405B2 (en) * | 2002-12-31 | 2006-12-26 | Symbol Technologies, Inc. | System for communicating product and service related information to a user based on direction of movement |
WO2004105359A2 (en) * | 2003-05-19 | 2004-12-02 | Einar Rosenberg | An apparatus and method for increased security of wireless transactions |
KR100456134B1 (ko) * | 2003-06-17 | 2004-11-10 | 김성수 | 판매되지 않은 소멸성 재화의 판매를 위한 일방시한쿠폰운용방법 |
CN1569893A (zh) * | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
US7418472B2 (en) * | 2003-09-30 | 2008-08-26 | Microsoft Corporation | Systems and methods for determining remote device media capabilities |
US7693827B2 (en) * | 2003-09-30 | 2010-04-06 | Google Inc. | Personalization of placed content ordering in search results |
US8073895B2 (en) * | 2004-06-01 | 2011-12-06 | Globaltel Media, Inc. | System and method for delivering web content to a mobile device |
JP2006012020A (ja) * | 2004-06-29 | 2006-01-12 | Aimnet Co Ltd | 発信番号表示を利用した注文確認システムと方法、及びこれを利用した取り引き実績のオンライン実績認証方法 |
US7689458B2 (en) * | 2004-10-29 | 2010-03-30 | Microsoft Corporation | Systems and methods for determining bid value for content items to be placed on a rendered page |
US20060178932A1 (en) * | 2005-02-07 | 2006-08-10 | Lang Brook W | Method and distribution system for location based wireless presentation of electronic coupons |
US8359611B2 (en) * | 2005-03-08 | 2013-01-22 | International Business Machines Corporation | Searchable television commercials |
US7437368B1 (en) * | 2005-07-05 | 2008-10-14 | Chitika, Inc. | Method and system for interactive product merchandizing |
US7660581B2 (en) * | 2005-09-14 | 2010-02-09 | Jumptap, Inc. | Managing sponsored content based on usage history |
US7912458B2 (en) * | 2005-09-14 | 2011-03-22 | Jumptap, Inc. | Interaction analysis and prioritization of mobile content |
US20070083611A1 (en) * | 2005-10-07 | 2007-04-12 | Microsoft Corporation | Contextual multimedia advertisement presentation |
US20070100690A1 (en) * | 2005-11-02 | 2007-05-03 | Daniel Hopkins | System and method for providing targeted advertisements in user requested multimedia content |
US20070113243A1 (en) * | 2005-11-17 | 2007-05-17 | Brey Thomas A | Targeted advertising system and method |
US7739358B2 (en) * | 2008-02-11 | 2010-06-15 | The Go Daddy Group, Inc. | Systems and methods for recommending website hosting applications |
US7729940B2 (en) * | 2008-04-14 | 2010-06-01 | Tra, Inc. | Analyzing return on investment of advertising campaigns by matching multiple data sources |
JP2013519162A (ja) * | 2010-02-01 | 2013-05-23 | ジャンプタップ,インコーポレイテッド | 統合化された広告システム |
-
2006
- 2006-04-17 CN CNB2006100756387A patent/CN100540047C/zh active Active
-
2007
- 2007-04-16 KR KR1020087027806A patent/KR101443233B1/ko active IP Right Grant
- 2007-04-16 CA CA002649768A patent/CA2649768A1/en not_active Abandoned
- 2007-04-16 US US12/226,491 patent/US20090305975A1/en not_active Abandoned
- 2007-04-16 WO PCT/CN2007/001246 patent/WO2007118431A1/zh active Application Filing
- 2007-04-16 EP EP07720819A patent/EP2011508B1/en not_active Not-in-force
- 2007-04-16 JP JP2009505708A patent/JP2009533478A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689878B2 (en) | 1998-09-15 | 2004-02-10 | The Regents Of The University Of California | Target of RNAIII activating protein (TRAP) |
US6747129B1 (en) | 1998-09-15 | 2004-06-08 | The Regents Of The University Of California | Target of RNAIII activating protein(TRAP) |
WO2005009396A2 (en) * | 2003-02-03 | 2005-02-03 | Naomi Balaban | Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
Non-Patent Citations (12)
Title |
---|
"Remongton, Science and Practice of Pharmacology", 1995, MACK PIBLISHING CO. |
BALABAN N. ET AL., SCIENCE, vol. 280, 1995, pages 438 - 440 |
BALABAN N. ET AL.: "Regulation of staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 4, 2001, pages 2658 - 2667, XP002984048 * |
GOV Y ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 14665 - 72 |
NAMOMI B. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 2658 - 2667 |
OLENY V. ET AL., PEPTIDES, vol. 22, 2001, pages 1621 - 1627 |
See also references of EP2011508A4 * |
SHEN TONG ET AL., JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 18, 2002, pages 623 - 626 |
W.R.PEARSON: "Rapid and Sensitive Sequence Comparison using FASTP and FASTA", METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63 - 98 |
W.R.PEARSON; D.J.LIPMAN: "Improved tools for Biological Sequence Analysis", PNAS, vol. 85, 2005, pages 2444 - 2448 |
YANG G. ET AL., J. BIOL. CHEM., vol. 280, 2005, pages 27431 - 27435 |
YANG G. ET AL., PEPTIDES, vol. 24, 2003, pages 1823 - 1828 |
Also Published As
Publication number | Publication date |
---|---|
KR101443233B1 (ko) | 2014-09-22 |
KR20090012237A (ko) | 2009-02-02 |
EP2011508A4 (en) | 2010-11-03 |
WO2007118431A8 (zh) | 2009-07-30 |
EP2011508B1 (en) | 2012-08-22 |
CN100540047C (zh) | 2009-09-16 |
US20090305975A1 (en) | 2009-12-10 |
CA2649768A1 (en) | 2007-10-25 |
CN1872335A (zh) | 2006-12-06 |
EP2011508A1 (en) | 2009-01-07 |
JP2009533478A (ja) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nie et al. | Outer membrane protein A (OmpA) as a potential therapeutic target for Acinetobacter baumannii infection | |
Geddes et al. | Unleashing the therapeutic potential of NOD-like receptors | |
JP5020078B2 (ja) | ペプチド | |
US20050163764A1 (en) | Treatment with agonists of toll-like receptors | |
US20190309021A1 (en) | Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase | |
JPH03501330A (ja) | カケクチンと反応するモノクロナール抗体 | |
EP1037650B1 (en) | Compositions for the treatment of staphylococcus aureus infections | |
CN112218659A (zh) | 用于治疗葡萄球菌感染的治疗性噬菌体组合物 | |
US7534857B2 (en) | Methods and compositions for the treatment and prevention of staphylococcal infections | |
US6761891B1 (en) | Medicament for treating a manifested lyme disease | |
JPH10509136A (ja) | ポリペプチドと自己−免疫疾患の治療および予防におけるその使用 | |
JP2002029999A (ja) | 消化性潰瘍の予防剤および治療剤 | |
WO2007118431A1 (zh) | Trap 蛋白自身作为活性成分在制备治疗金黄色葡萄球菌感染的药物中的应用 | |
JP2022536068A (ja) | クレブシエラの制御のためのクレビシン | |
Shen et al. | Molecular characterization and functional analyses of a hepcidin gene from Bostrychus sinensis | |
US20070071773A1 (en) | Compositions and methods for the treatment and prophylaxis of infections caused by gram positive bacteria | |
US6413510B1 (en) | Dimeric modified groβ protein | |
WO2003041726A1 (en) | Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug | |
WO2021242045A1 (ko) | Nlrx1 유래의 신규한 항염증성 펩타이드 및 이의 용도 | |
AU2017360043A1 (en) | Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes | |
US11161881B2 (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
EP1484066B1 (en) | 15k granulysin for the treatment of infections | |
NZ614460B2 (en) | Vaccines and compositions against streptococcus pneumoniae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07720819 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2649768 Country of ref document: CA Ref document number: 2009505708 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007720819 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027806 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12226491 Country of ref document: US |